Theravance Biopharma (TBPH) Cost of Revenue (2014 - 2018)

Theravance Biopharma (TBPH) has 5 years of Cost of Revenue data on file, last reported at $632000.0 in Q4 2018.

• On a quarterly basis, Cost of Revenue fell 72.52% year-over-year to $632000.0 in Q4 2018; TTM through Dec 2018 was $3.6 million, a 30.74% decrease from a year earlier, with the FY2018 full-year figure at $715000.0, down 88.14% from the prior year.
• Cost of Revenue for Q4 2018 stood at $632000.0, down from $705000.0 in the prior quarter.
• Over the last five years, Cost of Revenue for TBPH reached as high as $3.2 million in Q4 2014 and fell as low as $188000.0 in Q1 2014.
• Historically, Cost of Revenue has averaged $1.0 million across 5 years, with a median of $671500.0 in 2016.
• Across the five-year window, Cost of Revenue soared 196.69% in 2017 and tumbled 72.52% in 2018, its largest moves.
• Year by year, Cost of Revenue stood at $3.2 million in 2014, then dropped by 0.65% to $3.2 million in 2015, then tumbled by 64.2% to $1.1 million in 2016, then soared by 100.7% to $2.3 million in 2017, then tumbled by 72.52% to $632000.0 in 2018.
• Per Business Quant data, the three most recent Cost of Revenue figures were $632000.0 in Q4 2018, $705000.0 in Q3 2018, and $1.4 million in Q2 2018.